Daniel Lochner
Director of Finance/CFO at AVROBIO, INC.
Daniel Lochner active positions
| Companies | Position | Start | End |
|---|---|---|---|
| AVROBIO, INC. | Director of Finance/CFO | 2024-06-02 | - |
Career history of Daniel Lochner
Former positions of Daniel Lochner
| Companies | Position | Start | End |
|---|---|---|---|
Goldman Sachs Asset Management LP
 Goldman Sachs Asset Management LP Investment ManagersFinance Goldman Sachs Asset Management LP (GSAMLP) is a SEC-registered investment advisor headquartered in New York City. The firm is a wholly owned subsidiary of GSAM Holdings LLC, and their ultimate parent is Goldman Sachs Group, Inc. (NYSE: GS). Founded in 1988, GSAMLP provides investment solutions to a range of individual and institutional investors worldwide. | Portfolio Manager-Equities | 2005-06-30 | 2019-06-30 |
| OYSR POIN | Director of Finance/CFO | 2019-06-30 | - |
Training of Daniel Lochner
| University of Richmond | Undergraduate Degree |
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
Statistics
International
| United States | 6 |
Operational
| Director of Finance/CFO | 2 |
| Portfolio Manager-Equities | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 3 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| AVROBIO, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Goldman Sachs Asset Management LP
Goldman Sachs Asset Management LP Investment ManagersFinance Goldman Sachs Asset Management LP (GSAMLP) is a SEC-registered investment advisor headquartered in New York City. The firm is a wholly owned subsidiary of GSAM Holdings LLC, and their ultimate parent is Goldman Sachs Group, Inc. (NYSE: GS). Founded in 1988, GSAMLP provides investment solutions to a range of individual and institutional investors worldwide. | Finance |
Oyster Point Pharma, Inc.
 Oyster Point Pharma, Inc. Pharmaceuticals: MajorHealth Technology Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ. | Health Technology |
- Stock Market
- Insiders
- Daniel Lochner
- Experience
